Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Rare NRG1 fusion is an uncommon oncogenic alteration with a global prevalence of approximately 0.2% in solid tumors and 0.19–0.27% in non-small cell lung cancer, according to J Rodon et al., 2025. Higher rates up to 0.8% are reported in RNA-based cohorts, as per Breno Jeha Araújo et al., 2026. As per rare NRG1 fusion epidemiology forecast by Expert Market Research, prevalence is expected to remain rare but clinically significant due to its therapeutic relevance as an oncogenic driver.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Rare NRG1 Fusion – Number of Cases by Year

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rare NRG1 Fusion Epidemiology Forecast Report Coverage

Expert Market Research's “Rare NRG1 Fusion Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of rare NRG1 fusion. It projects the future incidence and prevalence rates of rare NRG1 fusion cases across various populations. The study covers age, gender, and type as major determinants of the rare NRG1 fusion population. The report highlights patterns in the prevalence of rare NRG1 fusion over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of rare NRG1 fusion in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Rare NRG1 Fusion Understanding: Disease Overview

Rare NRG1 fusion is a molecularly defined cancer subtype characterized by gene rearrangements involving the NRG1 gene, leading to aberrant activation of the ERBB signaling pathway. It occurs most commonly in non-small cell lung cancer and invasive mucinous adenocarcinoma. The alteration functions as a gene fusion that drives uncontrolled cellular proliferation through ERBB3/ERBB4 activation. According to clinical studies, prevalence ranges from 0.2% to 0.8%, depending on sequencing methodology. It is more frequently observed in female, non-smoking patients and is associated with aggressive disease biology and poor prognosis when untreated.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

India

High-Risk Population

Female Non-Smokers

Key Diagnostic Method

RNA-NGS

Major Risk Factor

Gene Fusion

Major gap in the market

Underdiagnosis

Rare NRG1 Fusion Epidemiology Perspective

The rare NRG1 fusion epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the rare NRG1 fusion epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for rare NRG1 fusion and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Breno Jeha Araújo et al., 2026, NRG1 fusions were identified in 12 of 1,536 NSCLC patients (0.8%), which is higher than historical DNA-only estimates of 0.2–0.3% reported by J Rodon et al., 2025. This indicates that RNA-based sequencing significantly improves detection accuracy and reveals previously underdiagnosed cases.

Gender-Specific Cases of the Disease

As per Breno Jeha Araújo et al., 2026, 83% of patients were female, indicating strong gender enrichment. According to study observations, this aligns with the high prevalence of invasive mucinous adenocarcinoma in female NSCLC patients, suggesting a biologically driven gender bias in fusion occurrence.

Age-Specific Cases of the Disease

According to Breno Jeha Araújo et al., 2026, the median age was 66 years, indicating that Rare NRG1 Fusion primarily affects older adults. As per clinical interpretation, this reflects accumulation of somatic genomic alterations over time in lung cancer development.

Ethnicity-Wise Cases of the Disease

As per J Rodon et al., 2025, NRG1 fusions have been reported across multiple tumor types globally including lung, breast, and cholangiocarcinoma.

Mortality and Survival Analysis of the Disease

According to Breno Jeha Araújo et al., 2026, median overall survival in stage IV patients was 7.9 months. As per study findings, poor survival outcomes were associated with lack of access to HER2–HER3–directed therapy and limited treatment response to conventional regimens.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

CD74–NRG1 Fusion

According to Shui Xiang et al., 2025, CD74 is the most common fusion partner, accounting for 29.3% of cases across NRG1 fusion-positive tumors.

SLC3A2–NRG1 Fusion

As per Breno Jeha Araújo et al., 2026, SLC3A2 is a frequent fusion partner (n = 3 cases), commonly observed in NSCLC molecular profiling datasets.

Other Fusion Partners (WRN, LIPE, VAMP2, SDC4)

According to Breno Jeha Araújo et al., 2026, these were observed as single-case events, reflecting molecular heterogeneity of NRG1 fusion tumors.

Overall Fusion Landscape

As per Shui Xiang et al., 2025, a total of 36 fusion partners have been identified across cancers, indicating high genomic diversity.

Rare NRG1 Fusion – Number of Cases by Country

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise Rare NRG1 Fusion Epidemiology

The rare NRG1 fusion epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

NRG1 fusion is a rare oncogenic alteration in NSCLC (~0.2–0.3%, according to J Rodon et al., 2025). The United States shows relatively higher identification due to extensive use of large-scale genomic profiling platforms, leading to better recognition of rare fusion-driven tumors in clinical practice.

Germany

In Germany, NRG1 fusion cases are infrequent and mainly detected through advanced molecular testing in lung cancer patients. The country benefits from structured oncology diagnostics, supporting identification of rare genomic drivers in specialized cancer centers.

France

France reports low but consistent detection of NRG1 fusion in NSCLC. Identification is primarily linked to increasing adoption of precision oncology workflows and broader use of molecular profiling in thoracic oncology units.

Italy

Italy shows frequency detection patterns, with NRG1 fusion mostly identified in adenocarcinoma subtypes of lung cancer through targeted or comprehensive genomic testing platforms.

Spain

Spain demonstrates gradual improvement in detection due to expanding next-generation sequencing access, though overall occurrence remains rare and primarily limited to advanced NSCLC cases.

United Kingdom

The United Kingdom shows rare occurrence patterns, with most cases identified through centralized molecular testing programs supporting precision oncology and biomarker-driven treatment selection.

Japan

Japan has reported low-frequency NRG1 fusion detection, with higher likelihood of identification in non-smoking adenocarcinoma patients due to stronger integration of RNA-based sequencing approaches.

India

In India, epidemiology is limited due to low widespread RNA-based sequencing. As molecular testing expands, detection of rare fusions like NRG1 is expected to increase, aligning with global rarity patterns but currently underdiagnosed in routine settings.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The Rare NRG1 Fusion landscape presents significant regional disparities in diagnostic capability and therapeutic access. According to published studies, RNA-based sequencing remains unevenly adopted across geographies, leading to underdiagnosis in many regions. As per global evidence from J Rodon et al., 2025 and Breno Jeha Araújo et al., 2026, regions with advanced molecular infrastructure such as North America and parts of Europe demonstrate higher detection rates compared to developing healthcare systems. Emerging growth opportunities are concentrated in Asia-Pacific, Latin America, and South Asia, where expanding next-generation sequencing adoption and precision oncology programs are improving molecular identification. The absence of approved targeted therapies globally further highlights unmet need across all regions, making precision diagnostics expansion the key growth driver.

Rare NRG1 Fusion: Treatment Overview

Treatment of rare NRG1 fusion primarily relies on targeted inhibition of the ERBB signaling pathway. Therapeutic approaches include pan-ERBB inhibitors, HER2/HER3-directed monoclonal antibodies, and investigational agents targeting ligand-receptor binding. The emergence of bispecific antibodies targeting HER2–HER3 heterodimerization has shown clinical promise. Current management also includes chemotherapy and chemoimmunotherapy, though responses remain limited. RNA-based diagnostics guide therapy selection by enabling accurate detection of fusion events. The treatment landscape is evolving toward precision medicine, with a strong focus on targeted therapy to improve outcomes in this rare oncogenic subset.

Key Questions Answered

  • What is the current and projected burden of rare NRG1 fusion across the 8 major markets?
  • Which countries across the 8 major markets account for the highest rare NRG1 fusion patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of rare NRG1 fusion across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of rare NRG1 fusion across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of rare NRG1 fusion across the 8 major markets?
  • How do major comorbidities and risk factors influence rare NRG1 fusion epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of rare NRG1 fusion across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Rare NRG1 Fusion landscape across the 8 major markets?
  • Which therapeutic areas linked to rare NRG1 fusion are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the rare NRG1 fusion epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on rare NRG1 fusion epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for rare NRG1 fusion across the 8 major markets?

Scope of the Rare NRG1 Fusion Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of rare NRG1 fusion based on several factors.
  • Rare NRG1 Fusion Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The rare NRG1 fusion report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Non-Small Cell Lung Cancer Pipeline Analysis Report

Precision Medicine Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us